摘要
目的观察缬沙坦对肝纤维化患者肝纤维化程度的影响。方法 60例肝纤维化患者随机分为对照组(28例)和治疗组(32例)。对照组予以恩替卡韦片,每次0.5 mg,每日1次,复方鳖甲软肝片,每次2 g,每天3次。治疗组在对照组基础上加用缬沙坦胶囊,每次80 mg,每日1次。2组疗程均为6个月。于治疗前后检测肝功能丙氨酸氨基转移酶(ALT)、谷草转氨酶(SGOT)、总胆红素(TBIL)和肝纤维化指标透明质酸(HA)、层粘联蛋白(LN)、Ш型前胶原(PC-Ш)、Ⅳ型胶原(Ⅳ-C)及Fibroscan值变化。结果治疗后,治疗组的血清肝功能指标ALT、SGOT、TBIL及肝纤维化指标LN、HA、PC-Ш、Ⅳ-C和Fibroscan值均较治疗前降低(P<0.05),且明显低于对照组(P<0.05)。结论缬沙坦胶囊联合恩替卡韦片和复方鳖甲软肝片治疗肝纤维化疗效确切。
Objective To investigate the influence of valsartan on fibrosis index of liver cirrhosis. Methods Total of sixty patients with liver cirrhosis were randomly divided into the trial group（n=32） and the control group（n=28）.The FuFang BieJia RuanGan tablets with the dose 2 g every time, twice a day for 6 treatment of control group. Before and after treatment, levels of serum fibroscan value of two groups were compared. Results After treatment, serum glutamic oxaloacetic transaminase（SGOT）, alanine aminotransferase （ALT）, total bilirubin（TBIL）,HA,LN,PC-III,Ⅳ-C of trial group were significantly lower than before（P＜0.05）. Fibroscan value was significantly lower too（P＜0.05）. All indexes of trial group were lower than those of control group, and the differences were statistically significant（P＜0.05）. Conclusion Valsartan combined entecacir,FuFang BieJia RuanGan tablets for treatment of liver cirrhosis has a curative effect.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第3期176-178,共3页
The Chinese Journal of Clinical Pharmacology
基金
南京市科技发展基金临床药学基金资助项目(2012YX014)
